2023 World Conference on Lung Cancer (Posters)-P1.21. Major Pathologic Response after Neoadjuvant Therapy in NSCLC: Predicting Better Outcomes with High Interobserver Agreement

P1.21. Major Pathologic Response after Neoadjuvant Therapy in NSCLC: Predicting Better Outcomes with High Interobserver Agreement - PDF(Slides)

Back to course

Pdf Summary

A study was conducted to investigate the reproducibility of assessing the major pathologic response (MPR) in patients with non-small cell lung cancer (NSCLC) after neoadjuvant therapy and its prognostic impact on patient outcomes. The study included 108 NSCLC patients who were treated with neoadjuvant therapy followed by surgical resection. Histologic assessment of the tumor bed was performed by three observers using the International Association for the Study of Lung Cancer (IASLC) recommendations.<br /><br />The results showed high interobserver agreement on the assessment of viable tumor percentage (VT) and MPR. The agreement was particularly strong at the extremes of VT percentages. MPR was associated with improved overall survival (OS), event-free survival (EFS), and lung cancer-specific survival (LCS). Patients with squamous cell carcinoma (SqCC) had a higher incidence of MPR cases and lower VT percentages compared to patients with adenocarcinoma (ADC). SqCC patients also had improved EFS outcomes.<br /><br />The study findings suggest that MPR is a significant predictor of better outcomes in NSCLC patients after neoadjuvant therapy. The results highlight the importance of assessing MPR as a surrogate marker for patient survival in the neoadjuvant setting. The study also demonstrates the importance of following the IASLC recommendations for histologic assessment to ensure accurate and reproducible results.<br /><br />In conclusion, the study shows that MPR is associated with improved patient outcomes and there is high interobserver agreement on its assessment. This information could be valuable in predicting outcomes and guiding treatment decisions in NSCLC patients undergoing neoadjuvant therapy.

Asset Subtitle

Sungjin Kim

Meta Tag

Speaker Sungjin Kim

Topic Pathology & Biomarkers: Biomarkers for Immuno-oncology

Keywords

reproducibility

major pathologic response

non-small cell lung cancer

neoadjuvant therapy

prognostic impact

interobserver agreement

viable tumor percentage

overall survival

lung cancer-specific survival

neoadjuvant setting